newsfilter
← Latest News
GlobeNewswire·

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral presentation to feature expanded and updated dataset from CARDINAL trial Cash,